Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Intuitive Surgical, Inc. (ISRG): Should Johnson & Johnson (JNJ) Be Looking for a Cougar in Devices?

Page 1 of 2

Several years ago, Johnson & Johnson (NYSE:JNJ) realized it had a problem with its drug business. This wasn’t a particularly poignant revelation, as the struggles of the business from around 2004 to 2010 were pretty easy to see, but the company went and did something about it. Licensing agreements with Bayer and Mitsubishi Tanabe brought in drugs like Xarelto and Invokana, while the billion-dollar acquisition of Cougar Biotechnology ultimately turned into the blockbuster prostate cancer drug Zytiga.

Johnson & Johnson (JNJ)I mention this because other parts of Johnson & Johnson (NYSE:JNJ) could use some TLC. Not only is the consumer/over-the-counter business still on a slow path to recovery from repeated product quality and recall issues, but the device business has turned into a perpetual disappointment with low organic sales growth. While the large acquisition of Synthes (announced in 2011, completed in 2012) has spiffed up the orthopedics business, I think it’s worth asking whether Johnson & Johnson (NYSE:JNJ) should think about going Cougar-hunting in the device space.

First, a word (or a hundred) against…
Let me start off by saying that, although the growth hasn’t been great lately, Johnson & Johnson (NYSE:JNJ) still has a pretty good device business. There aren’t many large med-tech companies showing all that much growth today, so it’s not as though Johnson & Johnson (NYSE:JNJ) is alone in reporting weak organic growth. What’s more, between areas like orthopedics and minimally invasive surgery, the company does have some areas of real strength.

It’s also worth noting that the device business isn’t like the drug business. You just don’t see multibillion-dollar “blockbuster” devices very often; even much-ballyhooed Intuitive Surgical, Inc. (NASDAQ:ISRG) generates about half the revenue that Boehringer Ingelheim‘s Spiriva generated in 2012, and that was the No. 15 drug in 2012. Likewise, Medtronic‘s entire market-leading cardiac rhythm management franchise generates only about 6% more in revenue than Spiriva did in 2012.

Even so, where could Johnson & Johnson (NYSE:JNJ) look for acquired growth in the med-tech world?

Surgical
With Johnson & Johnson’s strong Ethicon Endo-Surgery business, acquisitions here could be highly leverageable. Intuitive Surgical, Inc. (NASDAQ:ISRG) has always been a popular rumored target, as its da Vinci surgical robot is seen as both a competitor to the minimally invasive surgery businesses of J&J and Covidien , but also an avenue to converting more open surgeries to a minimally invasive approach. Unfortunately, while the growth is appealing, the price tag would be quite steep.

A smaller name, though, could make sense. Novadaq Technologies Inc. (NASDAQ:NVDQ) has developed some innovative imaging platforms that allow surgeons to better assess perfusion (blood flow) while they’re performing surgeries, leading to fewer complications.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!